|1.||Pulaski, Lukasz: 1 article (07/2015)|
|2.||Ryba, Katarzyna: 1 article (07/2015)|
|3.||Ratajewski, Marcin: 1 article (07/2015)|
|4.||Karwaciak, Iwona: 1 article (07/2015)|
|5.||Dastych, Jaroslaw: 1 article (07/2015)|
|6.||Gorzkiewicz, Michal: 1 article (07/2015)|
|1.||Melanoma (Melanoma, Malignant)
07/05/2015 - "Taken together, we conclude that the usage of AC-93253 in combined therapy could be a promising strategy for melanoma patients. "
07/05/2015 - "Here, we show for the first time that AC-93253, a SIRT2 inhibitor, exerts a negative effect on the expression of a set of genes involved in the progression and chemoresistance (e.g., oncogenes, apoptosis-related genes, ABC transporter genes, and cell cycle control genes) of melanoma cells. "
07/05/2015 - "AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation."
07/05/2015 - "Furthermore, melanoma cells exposed to AC-93253 and doxorubicin displayed altered biological responses, including apoptosis and proliferation, compared to cells exposed to single treatments. "